AT 9283

Drug Profile

AT 9283

Alternative Names: AT-9283

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astex Therapeutics
  • Developer Astex Pharmaceuticals; Astex Therapeutics; Cancer Research UK; National Cancer Institute (Canada)
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Bcr-abl tyrosine kinase inhibitors; Janus kinase-2 inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Medulloblastoma; Multiple myeloma; Myelofibrosis; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
  • 09 Jan 2013 NCIC Clinical Trials Group completes a phase I trial in solid tumours and non-Hodgkin's lymphoma (second-line therapy or greater, monotherapy) in United Kingdom (NCT00443976)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top